An Acoustofluidic Device for Biocompatible Platelet Separation

用于生物相容性血小板分离的声流控装置

• 批准号: 10256156
• 负责人: Lin Wang
• 金额: $ 77.13万
• 依托单位: ASCENT BIO-NANO TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-15 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10256156
• 关键词: Acoustics; Address; Affect; Animal Model; Benchmarking; Biochemical; Biological; Biomedical Research; Blood; Blood Cells; Blood Component Removal; Blood Platelets; Blood coagulation; Chemicals; Clinical; Clinical Research; Collection; Custom; Development; Devices; Effectiveness; Electronics; Ensure; Excision; Feedback; Goals; Gold; Half-Life; Hematology; Hemorrhage; Hospitals; Host Defense; In Vitro; Industry Standard; Laboratories; Life; Liquid substance; Measurement; Measures; Mechanics; Medical Device; Membrane; Methods; Military Personnel; Morphology; Neoplasm Metastasis; Oncology; Outcome; Patients; Performance; Phase; Physiological Processes; Platelet Activation; Platelet Count measurement; Platelet Transfusion; Play; Procedures; Process; Property; Reporting; Research; Research Personnel; Resources; Rest; Role; Rural; Sampling; Savings; Series; Small Business Innovation Research Grant; Speed; System; Systems Integration; Techniques; Technology; Test Result; Testing; Therapeutic; Transfusion; Universities; Whole Blood; Work; base; biomaterial compatibility; clinical application; commercialization; cost effective; design; improved; in vivo; instrument; meetings; microsystems; nanobiotechnology; nanoparticle; point of care; portability; prevent; prototype; success; tool; tumor; wound healing

Abstract Isolating a high-purity, high-quality, and high-concentration platelet sample in an efficient and cost- effective manner is of paramount importance to both hematological research and clinical therapy settings. Even though there are several methods for isolating platelets on the market today, most current methods have low biocompatibility (i.e., activate platelets, alter their morphology, and reduce membrane integrity during the platelet separation process). These drawbacks detract from the overall utility of current practices, and can even have a negative impact on patients. For example, measurements of platelet units in U.S. hospitals have found that platelet activation rates range between 23% to 50%. Studies have shown that when patients receive activated platelets, they require more platelet transfusion than patients who receive non-activated platelets. Overall, up to 30% of platelet transfusions performed in the U.S. are ineffective. Although there are many factors that influence the clinical outcomes of platelet transfusions, the quality of isolated platelets has been shown to play a crucial role. The objective of this SBIR project is to overcome the limitations of existing platelet separation technologies and address the unmet needs in the market by developing and commercializing a biocompatible platelet separation and enrichment platform using acoustofluidic (i.e., the fusion of acoustics and fluid mechanics) technologies. During our work on the Phase I project, we successfully demonstrated the utility and feasibility of the proposed biocompatible platelet separation and enrichment devices by meeting or exceeding the target values for each of the six key parameters identified in the Measures of Success. In Phase II, our commercialization activities will improve the performance of the acoustofluidic-based platelet separation and enrichment chips, develop self-contained, beta-testing-ready prototypes, and validate their performance with end users. The proposed acoustofluidic technology will have significantly improved biocompatibility when compared to the benchmark technologies (isolating platelets that are more morphologically and chemically intact). We believe that our superior biocompatibility compared to traditional platelet isolation techniques will enable the development and commercialization of an acoustofluidic platform that has the potential to significantly improve the effectiveness, speed, and economy of both clinical and research applications of platelets.

抽象的 以高效且成本低廉的方式分离高纯度、高质量和高浓度的血小板样本 有效的方法对于血液学研究和临床治疗都至关重要 设置。尽管当今市场上有多种分离血小板的方法，但目前大多数方法 方法具有低生物相容性（即，激活血小板，改变其形态，并减少膜 血小板分离过程中的完整性）。这些缺点有损于整体效用 目前的做法，甚至可能对患者产生负面影响。例如，测量 美国医院的血小板单位发现血小板活化率在 23% 至 50% 之间。 研究表明，当患者接受活化血小板时，需要更多的血小板输注 与接受非活化血小板的患者相比。总体而言，高达 30% 的血小板输注进行了 在美国是无效的。尽管影响血小板临床结果的因素有很多 在输血中，分离血小板的质量已被证明发挥着至关重要的作用。此举的目的 SBIR项目旨在克服现有血小板分离技术的局限性并解决 通过开发和商业化生物相容性血小板分离和商业化来满足市场上未满足的需求 使用声流体（即声学和流体力学的融合）技术的浓缩平台。 在一期项目的工作中，我们成功地证明了该方法的实用性和可行性。 提出的生物相容性血小板分离和富集装置达到或超过目标 成功衡量标准中确定的六个关键参数中每个参数的值。在第二阶段，我们的 商业化活动将提高基于声流控的血小板分离的性能 和丰富芯片，开发独立的、可进行 Beta 测试的原型，并验证其 最终用户的性能。所提出的声流控技术将得到显着改善 与基准技术相比的生物相容性（分离的血小板更 形态和化学上完整）。我们相信，与相比，我们具有卓越的生物相容性 传统的血小板分离技术将使血小板分离技术的开发和商业化成为可能。 声流控平台有可能显着提高效率、速度和 血小板临床和研究应用的经济性。